ZBIO
Zenas BioPharma, Inc.
$28.77
+1.09 (+3.92%)
At close · Jul 8
Market Cap
$1.86B
Shares
63,133,377
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.77
Open$27.36
Day$26.55–28.84
52W$9.85–44.60
Avg vol 30d885K
Short int11.1M · 17.6% float · 19.3d
Short vol58%
DataSep 2024–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+15%
above
Price vs 50-day avg
+42%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
54%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+63%
trailing
6-month return
+33%
trailing
YTD return
−21%
this year
Relative strength
+26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $25 — 200d above 50d
Institutional flow
Distributing
2 of 139 funds reported for Jun 30 · net -38 sh shares · +1 new
Insider flow
Accumulating
Net +$2.1M over 90 days · 0% sells
Short interest
Rising
17.63% of float · ▲ +2.3% MoM · 19.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
139 holders — near 1-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+100%
Y/Y
EPS growth
+29%
Y/Y
Free cash flow
$-172.4M
Balance sheet
$110.6M
net cash
Quant / Vol
risk profile
Volatility
113%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+15%
Bullish
Price vs 50-day avg
+42%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
54%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $20 › 200d $25 — 200d above 50d
Institutional flow
Distributing
2 of 139 funds reported for Jun 30 · net -38 sh shares · +1 new
Insider flow
Accumulating
Net +$2.1M over 90 days · 0% sells
Short interest
Rising
17.63% of float · ▲ +2.3% MoM · 19.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
139 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $10
Now $29 · 54%
52-wk high $45
vs 200-day avg +15%
vs 50-day avg +42%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZBIO
this stock
Zenas BioPharma, Inc.
|
$1.86B | -20.8% | +100.0% | — | 17.6% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZBIO | +13.3% | +63.3% | +33.4% | +13.3% | -20.8% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +13.5% | +62.5% | +25.9% | +13.5% | -30.1% |